2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyridines
AssigneeMead Johnson & Company
InventorsDavis L. Temple, Jr., Joseph P. Yevich, Walter G. Lobeck, Jr.
Life of this patent
Estimating the term…
Abstract
1-[4-(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]piperazines with 2-2-(3-cyano)pyridyl substituents in the 4- position have been synthesized and demonstrate useful psychotropic properties.
Claims7
A compound selected from the group consisting of a compound having Formula (I) ##STR15## wherein R.sup.1 and R.sup.2 are independently selected from C.sub.1 to C.sub.4 alkyl groups;
- with Z being hydrogen;
- halogen or pseudohalogen, preferably fluoro, chloro, or trifluoromethyl
- and the non-toxic pharmaceutically acceptable acid addition salts thereof.
The process for ameliorating an undesirable anxiety/antipsychotic state in a mammal comprising systemic administration to said mammal of an effective psychotropic dose of from 0.01 to 40 mg/kg body weight of a Formula (I) compound or a pharmaceutically acceptable acid addition salt thereof.
A pharmaceutical composition in dosage unit form suitable for systemic administration to a mammalian host comprising a pharmaceutical carrier and an amount of a Formula (I) compound to provide an effective non-toxic dose of from 0.01 to 40 mg/kg body weight of said host.
Dependencies are inferred from the claim text.